Atrium Therapeutics: PIPE offering of 5,170,384 shares

What happened

• Atrium Therapeutics reported in Amendment No. 1 to its Form 8-K that, as previously disclosed in the Original Form 8-K, on Oct 7, 2026 the company entered into a securities purchase agreement with selected investors that qualify as “accredited investors” (the “PIPE Investors”) to sell an aggregate of 5,170,384 shares of common stock and pre-funded warrants to purchase up to 1,134,930 shares (the “Offering”).
• The filing states that following the Offering the company will have 21,571,507 shares of common stock outstanding, which includes shares issued in connection with the settlement of the make whole equity awards made in connection with its spin-off from Avidity Biosciences, Inc.

Key details

• Date of agreement: Oct 7, 2026.
• Shares to be sold: 5,170,384 shares of common stock.
• Pre-funded warrants: to purchase up to 1,134,930 shares of common stock.
• Shares outstanding after Offering: 21,571,507 shares of common stock.
• The amendment contains forward-looking statements about the expected closing of the Offering and identifies related risks and conditions described in the company’s periodic reports.

Why it may matter

• Item reported: Item 8.01, other events. The item covers disclosure that the company entered into the securities purchase agreement for the PIPE Offering and that the amendment includes forward-looking statements about the expected closing and related risks.
• A filing does not show why the insider traded or why the company acted.